All News

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

Your daily dose of the clinical news you may have missed.

Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.

Your daily dose of the clinical news you may have missed.

THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.

The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.

In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.

Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.

Your daily dose of the clinical news you may have missed.

The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.

The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.

Even activity levels considered "insufficient" by guideline standards were found protective against stroke in this new systematic review and meta-analysis.

Your daily dose of the clinical news you may have missed.

A CPT code for time spent petitioning insurance companies to approve patient prescriptions has been proposed before; sentiment was not unanimous.

Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.

Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

Your daily dose of the clinical news you may have missed.

Melatonin products, particularly flavored gummies and tablets, were documented in 7 out of 10 ED visits for unsupervised medication exposure in children aged ≤5 years.